Welcome to our dedicated page for CBIS news (Ticker: CBIS), a resource for investors and traders seeking the latest updates and insights on CBIS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CBIS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CBIS's position in the market.
Cannabis Science Inc. (CBIS) has launched the $CSI Cannabis Science Coin, aimed at asset valuation and dividend disbursements for its CSi-EDP projects. This new cryptocurrency will facilitate transactions within the company's ecosystem, enhancing its international reach and multiplying its value. Additionally, Cannabis Science is undergoing acquisition by Thermic Science International Corporation, with regulatory filings currently in progress. Shareholders will be notified post-transaction completion. The company projects significant growth through its cannabinoid research initiatives and potential FDA drug developments targeting critical ailments.
Cannabis Science Inc. (CBIS) has launched the $CSI Cannabis Science Coin, aimed at enhancing project asset valuations and dividend disbursements through its CSi-EDP initiative. This launch is critical as it enables Cannabis Science to tap into its significant cannabinoid research assets and aims to grow its international reach. An acquisition by Thermic Science International is underway, with all shareholders expected to benefit from asset valuations. The company anticipates potential cash dividends of approximately 25% from its projects while focusing on FDA-targeted drug development for critical ailments.
